Results 11 to 20 of about 186,531 (283)

Current patterns of beta‐blocker prescription in cardiac amyloidosis: an Italian nationwide survey

ESC Heart Failure, 2021
Aims The use of beta‐blocker therapy in cardiac amyloidosis (CA) is debated. We aimed at describing patterns of beta‐blocker prescription through a nationwide survey.
Giacomo Tini, Francesco Cappelli, Elena Biagini, Beatrice Musumeci, Marco Merlo, Lia Crotti, Matteo Cameli, Gianluca Di Bella, Alberto Cipriani, Francesca Marzo, Federico Guerra, Cinzia Forleo, Christian Gagliardi, Mattia Zampieri, Samuela Carigi, Pier Filippo Vianello, Giulia Elena Mandoli, Giuseppe Ciliberti, Luca Lichelli, Davide Mariani, Aldostefano Porcari, Domitilla Russo, Roberto Licordari, Alberto Ponziani, Italo Porto, Federico Perfetto, Camillo Autore, Claudio Rapezzi, Giafranco Sinagra, Marco Canepa   +29 more
doaj   +2 more sources

Effect of beta blocker use and type on hypoglycemia risk among hospitalized insulin requiring patients

Cardiovascular Diabetology, 2019
Background Although beta blockers could increase the risk of hypoglycemia, the difference between subtypes on hypoglycemia and mortality have not been studied.
Kathleen Dungan, Jennifer Merrill, Clarine Long, Philip Binkley   +3 more
doaj   +2 more sources

Influence of beta-blocker therapy on the risk of infections and death in patients at high risk for stroke induced immunodepression. [PDF]

PLoS ONE, 2018
Stroke-induced immunodepression is a well characterized complication of acute ischemic stroke. In experimental studies beta-blocker therapy reversed stroke-induced immunodepression, reduced infection rates and mortality.
Ilko L Maier, Johannes C Becker, Johanna Rosemarie Leyhe, Marlena Schnieder, Daniel Behme, Marios-Nikos Psychogios, Jan Liman   +6 more
doaj   +2 more sources

Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. [PDF]

Journal of the American College of Cardiology, 2019
BACKGROUND: Moderate and moderately severe renal impairment are common in patients with heart failure and reduced ejection fraction, but whether beta-blockers are effective is unclear, leading to underuse of life-saving therapy.
Andersson, B, Anker, SD, Beta-Blockers in Heart Failure Collaborative Group, Böhm, M, Cleland, JGF, Coats, AJS, Damman, K, Flather, MD, Gill, SK, Holmes, J, Kjekshus, J, Kotecha, D, Manzano, L, McMurray, JJV, Packer, M, Redon, J, Rigby, AS, Rosano, G, Ruschitzka, F, van Veldhuisen, DJ, von Lueder, TG, Wedel, H, Wikstrand, J   +22 more
core   +9 more sources

Effect of beta-blocker therapy on the risk of infections and death after acute stroke--a historical cohort study. [PDF]

PLoS ONE, 2015
BACKGROUND:Infections are a frequent cause for prolonged hospitalization and increased mortality after stroke. Recent studies revealed a stroke-induced depression of the peripheral immune system associated with an increased susceptibility for infections.
Ilko L Maier, André Karch, Rafael Mikolajczyk, Mathias Bähr, Jan Liman   +4 more
doaj   +2 more sources

Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines.

HYPERTENSION, 2022
Several hypertension guidelines have removed beta-blockers from their previous position as first-choice drugs for the treatment of hypertension. However, this downgrading may not be justified by available evidence because beta-blockers lower blood ...
G. Mancia, S. Kjeldsen, R. Kreutz, A. Pathak, G. Grassi, M. Esler   +5 more
semanticscholar   +1 more source

Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison

Respiratory Research, 2021
Background Beta-blockers are associated with reduced mortality in patients with cardiovascular disease but are often under prescribed in those with concomitant COPD, due to concerns regarding respiratory side-effects.
C. Gulea, R. Zakeri, V. Alderman, Alexander Morgan, J. Ross, J. Quint   +5 more
semanticscholar   +1 more source

Effect of beta‐blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy

European Journal of Heart Failure, 2022
In the EXPLORER‐HCM trial, mavacamten improved exercise capacity and symptoms in patients with obstructive hypertrophic cardiomyopathy (oHCM). Mavacamten effects on the primary endpoint, a composite of peak oxygen consumption (VO2) and New York Heart ...
M. Wheeler, D. Jacoby, P. Elliott, S. Saberi, Sheila M. Hegde, N. Lakdawala, J. Myers, A. Sehnert, J. Edelberg, Wanying Li, I. Olivotto   +10 more
semanticscholar   +1 more source

Beta-Blocker Exposure and Survival in Patients With Transthyretin Amyloid Cardiomyopathy.

Mayo Clinic proceedings, 2021
OBJECTIVE To investigate a potential association between beta-blocker exposure and survival in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
G. Barge-Caballero, E. Barge-Caballero, M. López-Pérez, R. Bilbao-Quesada, E. González-Babarro, I. Gómez-Otero, Andrea López-López, Mario Gutiérrez-Feijoo, A. Varela‐Román, C. González-Juanatey, Ó. Díaz-Castro, M. Crespo-Leiro   +11 more
semanticscholar   +1 more source

Beta‐blocker use and mortality among patients with systolic heart failure and pacemaker rhythm

ESC Heart Failure, 2023
Aims Beta‐blockers are proven to improve survival among patients with heart failure with reduced ejection fraction. Their efficacy in patients with heart failure with reduced ejection fraction and pacemaker devices has not been demonstrated.
Andrew S. Perry, Aldo P. Maggioni, Luigi Tavazzi, Wayne C. Levy   +3 more
doaj   +1 more source